Evidence map›Paper›PMID 40616738›Full record

ReviewJournal of endocrinological investigation2025

Role of the E26 transformation specific transcription factor family in metabolic disorders.

Mingxia Yang, Lili Gao, Bo Xu, Weiyi Li, Canyu Chen, Jixiang Chen, Jiecan Zhou

Abstract readReview
PubMed Publisher
In one paragraph

Review in Journal of endocrinological investigation, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Mingxia YangThe First Affiliated Hospital, Hunan Provincial Clinical Medical Research Center for Drug Evaluation of Major Chronic Diseases, Hengyang Medical School, University of South China, Hengyang, 421001, Hunan, China.
Lili GaoThe First Affiliated Hospital, Hunan Provincial Clinical Medical Research Center for Drug Evaluation of Major Chronic Diseases, Hengyang Medical School, University of South China, Hengyang, 421001, Hunan, China.
Bo XuThe First Affiliated Hospital, Hunan Provincial Clinical Medical Research Center for Drug Evaluation of Major Chronic Diseases, Hengyang Medical School, University of South China, Hengyang, 421001, Hunan, China.ORCID http://orcid.org/0000-0003-0594-9103
Weiyi LiThe First Affiliated Hospital, Hunan Provincial Clinical Medical Research Center for Drug Evaluation of Major Chronic Diseases, Hengyang Medical School, University of South China, Hengyang, 421001, Hunan, China.
Canyu ChenThe First Affiliated Hospital, Hunan Provincial Clinical Medical Research Center for Drug Evaluation of Major Chronic Diseases, Hengyang Medical School, University of South China, Hengyang, 421001, Hunan, China.
Jixiang ChenThe First Affiliated Hospital, Hunan Provincial Clinical Medical Research Center for Drug Evaluation of Major Chronic Diseases, Hengyang Medical School, University of South China, Hengyang, 421001, Hunan, China.
Jiecan ZhouThe First Affiliated Hospital, Hunan Provincial Clinical Medical Research Center for Drug Evaluation of Major Chronic Diseases, Hengyang Medical School, University of South China, Hengyang, 421001, Hunan, China. zhoujiecan@fsyy.usc.edu.cn.ORCID http://orcid.org/0000-0002-3037-3997

Funding

Clinical "4310" Project of the University of South China 20224310NHYCG02Hunan Province Clinical Medical Technology Innovation Guidance Project 2020SK51823, 2021SK51828, 2021SK51823Hunan Provincial Clinical Medical Research Center for Drug Evaluation of major chronic diseases 2023SK4040Natural Science Foundation of Hunan Province 2022JJ50163Natural Science Foundation of Hunan Province 2023JJ20034NSFC 82003872The science and technology innovation Program of Hunan Province 2023RC3173
6 · The paper itself

Abstract

Metabolic homeostasis is precisely regulated by transcription factors. Over the past two decades, the E26 transformation-specific (ETS) transcription factor family has been implicated in a variety of physiological and pathological processes through regulation of cell proliferation, differentiation and apoptosis. However, new evidence indicates that members of the ETS transcription factor family are closely related to metabolism and metabolic diseases, exhibiting functional heterogeneity in metabolic regulation: some members drive metabolic disorders, while others play a compensatory protective role. This review focuses on ETS1 and ETV5, which are among the most intensively studied transcription factors in the field. ETS1 promotes weight gain primarily by inhibiting beige adipocyte formation and adipocyte thermogenesis, Additionally, it promotes hepatocyte apoptosis and inflammation, thereby aggravating nonalcoholic steatohepatitis (NASH). Moreover, ETV5 is generally anti-inflammatory and has profound effects on lipolysis. As new data on the role of other ETS transcription factor family members in metabolic homeostasis continue to emerge, their importance in the study of metabolic diseases is becoming increasingly evident. This review provides a comprehensive overview of the role of the ETS family in metabolism, thereby facilitating the development of novel therapeutic strategies for metabolic diseases involving the ETS family.

Indexed as

Metabolic DiseasesProto-Oncogene Proteins c-etsTranscription FactorsAnimalsHumansProto-Oncogene Proteins c-etsTranscription FactorsETS1ETS familyETV5MetabolismMetabolism-related diseaseTranscription factor

Identifiers

PMID40616738

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.